官方服务：
资源简介：
PD-L1 & PD1 in lung sarcomatoid carcinoma
应用场景：
创建时间：
2017-06-14
相关数据集
DataSheet4_A systematic pan-cancer analysis reveals the clinical prognosis and immunotherapy value of C-X3-C motif ligand 1 (CX3CL1).ZIP
It is now widely known that C-X3-C motif ligand 1 (CX3CL1) plays an essential part in the process of regulating pro-inflammatory cells migration across a wide range of inflammatory disorders, includin
NIAID Data Ecosystem00
Transcriptomic Profiling of Peripheral Immune Cells in a Trial of Ruxolitinib with Nivolumab for PD1 non-responsive cHL
Treatment with checkpoint inhibitors is effective in multiple cancer types. However, even in cancers with high response rates such as Hodgkin lymphoma, some patients fail to respond or relapse followi
NIAID Data Ecosystem00
Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
This is a Phase 1/2, first-in-human, open-label, dose escalation and dose-expansion study of E-602, administered alone and in combination with cemiplimab.
NIAID Data Ecosystem10
A microRNA-regulated transcriptional state defines intratumoral CD8+T cells that respond to immunotherapy. A microRNA-regulated transcriptional state defines intratumoral CD8+T cells that respond to immunotherapy
Rising rates of advanced-stage colorectal cancer (CRC) and poor survival rates necessitate effective therapeutic options. Immune checkpoint inhibition (ICI), specifically anti-PD-1 therapy, shows pote
NIAID Data Ecosystem00
